medigraphic.com
Revista Médica Sinergia

2021, Number 02

<< Back Next >>

Revista Médica Sinergia 2021; 6 (02)

The manegement of anovulatory infertility in polycystic ovary syndrome

Otoya CF, León QS, Rodríguez MM

Language: Spanish
References: 36
Page: 1-13
PDF size: 187.98 Kb.


ABSTRACT

Anovulatory infertility is a common complication associated with polycystic ovary syndrome. Health optimization is the first step in the management of this pathology, specially focused on lifestyle changes and optimal body mass index. About pharmacotherapy, clomiphene citrate is used worldwide as a first line treatment to induce ovulation. However, letrozol and a combination of clomiphene citrate plus metformin have shown to be superior to clomiphene citrate in monotherapy, concerning fertility. These are still considered second line treatment due to lack of consensus. Exogenous gonadotropins and laparoscopic ovarian drilling are used when first-line treatment resistance is determined. Once first- and second-line treatment have failed, in-vitro fertilization is an option. Other drugs are being studied to determine their efficacy on this pathology, such as glucagon-like peptide 1 receptor agonists and inositol stereoisomers, but higher quality studies are still required.


REFERENCES

  1. Wang R, Li W, Bordewijk EM, Legro RS, Zhang H, Wu X, et al. First-line ovula- tion induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update. 2019;25:717– 32. https://doi.org/10.1093/humupd/dmz029

  2. Bergh C, Moore M, Gundell C. Evidence-Based Management of Infertility in Women With Polycystic Ovary Syndrome. JOGNN. 2016;45:111-122. http://dx.doi.org/10.1016/j.jogn.2015.10.001

  3. Zhang J, Si Q, Li J. Therapeutic effects of metformin and clomiphene in combination with lifestyle intervention on infertility in women with obese polycystic ovary syndrome. Pak J Med Sci. 2017;33(1):8-12. doi: https://doi.org/10.12669/pjms.331.11764

  4. Giviziez C, Sanchez E, Approbato M, Maia M, Fleury E et al. Obesity and anovulatory infertility: A review. JBRA Assisted Reproduction. 2016;20(4):240-245. https://doi.org/10.5935/1518-0557.20160046

  5. Mascarenhas M, Balen A. Treatment update for anovulation and subfertility in polycystic ovary syndrome. Current Opinion in Endocrine and Metabolic Research. 2020;12:53–58. https://doi.org/10.1016/j.coemr.2020.03.003

  6. Khan A, Karim N, Ainuddin J. The Triad Of PCOS, Infertility And Metformin. JBUMDC. 2019;9(1):67-71.

  7. Foroozanfard F, Samimi M, Almadani K, Sehat M. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome. Electronic Physician. 2017;9(12):5969-5973. https://doi.org/10.19082/5969

  8. Balen A, Morley L, Misso M, Franks S, Legro R, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687-708. https://doi.org/10.1093/humupd/dmw025

  9. Sánchez C. Factores que influyen en la tasa de embarazo en mujeres obesas en tratamiento con inseminación artificial. NURE Inv. 2013;10(62).

  10. Obirikorang C, Owiredu W, Adu-Afram S, Acheampong E, Asamoah E,et al. Assessing the variability and predictability of adipokines (adiponectin, leptin, resistin and their ratios) in non-obese and obese women with anovulatory polycystic ovary syndrome. BMC Res Notes. 2019;12:513. https://doi.org/10.1186/s13104-019-4546- z.

  11. Vivas C, Calderón C, Pulido E. Adiponectina y Reproducción. Rev Desafíos. 2013;1(7). Accesado el 24 de setiembre 2020, en: http://revistas.ut.edu.co/index.php/desafios/article/view/439

  12. Fichman V, Costa RS, Miglioli TC, Marinheiro LP. Association of obesity and anovulatory infertility. Einstein (São Paulo). 2020;18:eAO5150. http://dx.doi.org/10.31744/einstein_journal/2020AO5150

  13. Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: a prospective randomized trial. J Hum Reprod Sci. 2012;5:262–265. https://doi.org/10.4103/0974-1208.106338

  14. Franik S, Eltrop SM, Kremer JAM, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.TheCochrane database of systematic reviews.2018;5(5). https://doi.org/10.1002/14651858.CD010287.pub3

  15. Wang R, Kim BV, van Wely M, Johnson NP, Costello M, et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017;356:j138. https://doi.org/10.1136/bmj.j138

  16. Debras E, Fernandez H, Neveu ME, Deffieux X, Capmas P. Ovarian drilling in polycystic ovary syndrome: Long term pregnancy rate. Eur J Obstet Gynecol Reprod Biol X. 2019;4:100093. https://doi.org/10.1016/j.eurox.2019.100093

  17. Yu Q, Hu S, Wang Y, Cheng G, Xia W, et al. Letrozole versus laparoscopic ovarian drilling in clomiphene citrateresistant women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2019;17:17. https://doi.org/10.1186/s12958-019-0461-3

  18. Costello M, Garad R, Hart R, Homer H, Johnson L,et al. A Review of Second- and Third-line Infertility Treatments and Supporting Evidence in Women with Polycystic Ovary Syndrome. Med Sci. 2019;7,75. https://doi.org/10.3390/medsci7070075

  19. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017;108:426–441. https://doi.org/10.1016/j.fertnstert.2017.06.026

  20. Sam S, Ehrmann D. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017;60:1656–1661. https://doi.org/10.1007/s00125-017-4306-3

  21. Zeng XL, Zhang YF, Quan T, Xue Y, An RF. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome. Medicine. 2016;95(36). https://doi.org/10.1097/MD.0000000000004526

  22. Practice Committee of the American Society for Reproductive Medicine. Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committe opinion. Fertil Steril. 2020;113(1):66-69. https://doi.org/10.1016/j.fertnstert.2019.09.020

  23. Weiss NS, Kostova E, Nahuis M, Mol BWJ, van der Veen F, et al.Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2019;1:CD010290. https://doi.org/10.1002/14651858.CD010290.pub3

  24. Hong K, Franasiak J, Werner M, Patounakis G, Juneau C, et al. Embryonic aneuploidy rates are equivalent in natural cycles and gonadotropin-stimulated cycles. Fertil Steril. 2020;112(4):670-676. https://doi.org/10.1016/j.fertnstert.2019.05.039

  25. Bordewijk EM, Ng KYB, Rakic L, Mol BWJ, Brown J, Crawford TJ, et al. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2020;2:CD001122. https://doi.org/10.1002/14651858.CD001122.pub5

  26. Abu Hatem, Foda O, Rakhawy M. Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta analysis of randomized trials. Arch Gynecol Obstet. 2018;297:859-870. https://doi.org/10.1007/s00404- 018-4680-1

  27. Elshewy N, Ji D, Zhang Z, Chen D, Chen B, et al. Association between mild stimulated IVF/M cycle and early embryo arrest in sub fertile women with/without PCOS. Reprod Biol Endocrinol. 2020;18:71. https://doi.org/10.1186/s12958-020-00622-y

  28. Walls M, Junk S, Ryan JP, Hart R. IVF versus ICSI for the fertilization of in-vitro matured human oocytes. rBMO. 2012;25:603-607.https://doi.org/10.1016/j.rbmo.2012.08.001

  29. 29. Swanton A, Storey L, McVeigh E, Child T. IVF outcome in women with PCOS, PCO and normal ovarian morphology.Eur J Obstet Gynecol Reprod Biol. 2010;149:68-71 https://doi.org/10.1016/j.ejogrb.2009.11.017

  30. Mateo HA, Rentería GA, Frausto JA, Mateo M y col. Administración de metformina en mujeres con síndrome de ovario poliquístico y su efecto en fertilización in vitro. Reproducción (México). 2018;9(2):31-37.

  31. Zhou H, Zhang D, Luo Z, Yang A, Cui N, et al. Association between Body Mass Index and Reproductive Outcome in Women with Polycystic Ovary Syndrome Receiving IVF/ICSI-ET. BioMed Research International. 2020;2020:6434080. https://doi.org/10.1155/2020/6434080

  32. Salamun V, Jensterle M, Janez A, Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1-11. https://doi.org/10.1530/EJE-18-0175

  33. Cena H, Chiovato L, Nappi Rossella. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP- 1 Receptor Agonists. Clin Endocrinol Metab. 2020;105(8):e2695-e2709. https://doi.org/10.1210/clinem/dgaa285

  34. Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. rBMO. 2019;39(2):332-342. https://doi.org/10.1016/j.rbmo.2019.04.017

  35. Carmona IO, Saucedo E, Moraga MR, Romeu A. Mioinositol en combinación con D-chiro-inositol: resultados preliminares en el tratamiento de primera línea de pacientes con síndrome de ovario poliquístico. Ginecol Obstet Mex. 2017;85(3):141-151.

  36. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2018;12:CD012378. https://doi.org/10.1002/14651858.CD012378.pub2




2020     |     www.medigraphic.com